Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Jinhai Medical Technology's Median PS Value or its related term are showing as below:
HKSE:02225's Price-to-Median-PS-Value is not ranked *
in the Conglomerates industry.
Industry Median: 0.99 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Jinhai Medical Technology (HKSE:02225) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Jinhai Medical Technology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
6.105
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinhai Medical Technology Median PS Value Related Terms
Jinhai Medical Technology Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02225 vs RHI, KFY, TNET: Median PS Value Comparison
For the Conglomerates subindustry, Jinhai Medical Technology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinhai Medical Technology Price-to-Median-PS-Value vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Jinhai Medical Technology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Jinhai Medical Technology's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.075.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinhai Medical Technology (HKSE:02225) has a Median PS Value of HK$0.00 as of Sep. 10, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jinhai Medical Technology and its competitors. According to the industry distribution chart, Jinhai Medical Technology ranks #999999 out of 405 companies in the Conglomerates industry.
Is Jinhai Medical Technology's Median PS Value too high?
Jinhai Medical Technology's current Median PS Value is HK$0.00. Based on the distribution chart, Jinhai Medical Technology ranks #999999 out of 405 companies in the Conglomerates industry, which is in the bottom quartile relative to peers. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's Median PS Value compare to RHI and KFY?
According to the Conglomerates industry distribution chart, Jinhai Medical Technology ranks #999999 out of 405 companies for Median PS Value. This places Jinhai Medical Technology in the lower half of its industry. The industry median Median PS Value is 0.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Conglomerates company?
The median Median PS Value among Conglomerates companies is 0.99, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jinhai Medical Technology and its competitors. For the Conglomerates industry, the median Median PS Value is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinhai Medical Technology's current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.11 — trading 333% above its estimated fair value. The current Median PS Value is HK$0.00. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current Median PS Value is HK$0.00 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?
Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued.
The current stock price of HK$6.11 is trading 333% above its estimated GF Value™ of HK$1.41.
GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02225:
Median PS Value: HK$0.00
GF Value™: HK$1.41 vs. price of HK$6.11 (333% above fair value)
No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score
Get the complete analysis for HKSE:02225
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02225 has been successfully added to your 
